Receptor crosstalk: Haloperidol treatment enhances A2A adenosine receptor functioning in a transfected cell model

Purinergic Signalling

Volumn 6, Issue 4, 2010, Pages 373-381

  Trincavelli, Maria Letizia ^a   Cuboni, Serena ^a   Dell'Osso, Mario Catena ^a   Maggio, Roberto ^b   Klotz, Karl Norbert ^c   Novi, Francesca ^a   Panighini, Anna ^a   Daniele, Simona ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

A2A adenosine receptors; A2A binding parameters; D2 dopamine receptor antagonists; Receptor crosstalk; Receptor functioning

Indexed keywords

EID: 79651473855     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-010-9201-z     Document Type: Article

References (49)

1. Boison D (2007) Adenosine as a modulator of brain activity. Drug News Perspect 20: 607-611.
2. 2a-receptors. Glia 18: 152-160.
3. 2a adenosine receptor gene. J Neurochem 66: 362-368.
4. 2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 429: 139-142.
5. 2A receptors. Prog Neurobiol 59: 355-396.
6. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431: 331-346.
7. Yu L, Frith MC, Suzuki Y, Peterfreund RA, Gearan T, Sugano S, Schwarzschild MA, Weng Z, Fink JS, Chen JF (2004) Characterization of genomic organization of the adenosine A(2A) receptor gene by molecular and bioinformatics analyses. Brain Res 1000: 156-173.
8. 2A receptors. Curr Pharm Des 14: 1490-1499.
9. Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7: 759-770.
10. 2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49: 727-735.
11. Trincavelli ML, Melani A, Guidi S, Cuboni S, Cipriani S, Pedata F, Martini C (2008) Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain. J Neurochem 104: 479-490.
12. Deckert J, Brenner M, Durany N, Zöchling R, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Riederer P (2003) Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. NeuroReport 14: 313-316.
13. 2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with classical antipsychotics. J Psychiatr Res 40: 81-88.
14. Baldessarini RJ (2002) Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 16: 721-729.
15. Brambilla P, Barale F, Soares JC (2003) Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology 166: 315-332.
16. Sundram S, Joyce PR, Kennedy MA (2003) Schizophrenia and bipolar affective disorder: perspectives for the development of therapeutics. Curr Mol Med 3: 393-407.
17. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neurosci 63: 765-773.
18. 2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 14: 1468-1474.
19. 2 receptor heteromerization. Neuropsychopharmacology 34: 972-986.
20. 2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14: 186-195.
21. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278: 46741-46749.
22. 2 heteromeric receptor complexes and their function. J Mol Neurosci 26: 209-220.
23. 2 receptor hetero-oligomerization: a hypothesis that may explain behavioral sensitization to psychostimulants and schizophrenia. Med Hypotheses 64: 197-200.
24. 2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Scientific World Journal 8: 1088-1097.
25. Vidi PA, Chemel BR, Hu CD, Watts VJ (2008) Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells. Mol Pharmacol 74: 544-751.
26. Dixon DA, Fenix LA, Kim DM, Raffa RB (1999) Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother 33: 480-488.
27. Wardas J (2008) Potential role of adenosine A2A receptors in the treatment of schizophrenia. Front Biosci 13: 4071-4096.
28. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357: 1-9.
29. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
30. 1-adenosine receptors. J Biol Chem 260: 14659-14664.
31. 2A receptors are up-regulated in Pick's disease frontal cortex. Brain Pathol 16: 249-255.
32. 2 receptors. J Biol Chem 277: 18091-18097.
33. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psych 158: 360-369.
34. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99: 463-472.
35. 2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology 124: 285-287.
36. 2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31: 1991-2001.
37. Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, García-Ribera C, Gomeni R, Merlo-Pich E (2008) Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 22: 882-894.
38. Ritter LM, Meador-Woodruff JH (1997) Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression. Biol Psychiatry 42: 155-164.
39. Florijn WJ, Tarazi FI, Creese I (1997) Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280: 561-569.
40. Reuss B, Unsicker K (2001) Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes. Mol Cell Neurosci 18: 197-209.
41. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17: 82-91.
42. 2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord 10: 265-271.
43. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80: 262-270.
44. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 83: 310-331.
45. 2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock 32: 578-585.
46. Kochanek PM, Hendrich KS, Jackson EK, Wisniewski SR, Melick JA, Shore PM, Janesko KL, Zacharia L, Ho C (2005) Characterization of the effects of adenosine receptor agonists on cerebral blood flow in uninjured and traumatically injured rat brain using continuous arterial spin-labeled magnetic resonance imaging. J Cereb Blood Flow Metab 25: 1596-1612.
47. 2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J Trauma 53: 225-229.
48. 2A analogue reduces long-term neurologic injury after blunt spinal trauma. J Surg Res 121: 130-134.
49. 2A agonist for attenuation of spinal cord injury after thoracic aortic crossclamping. Ann Thorac Surg 81: 902-909.